


# making immuno-oncology therapeutics more targeted and potent than ever before

With its stealth virus platform technology, **Trocept**, Accession Therapeutics is focused on treating some of the most intractable and widespread forms of cancer. Led by immuno-oncology pioneer Bent Jakobsen, PhD FMedSci, the company is accelerating a pipeline of highly differentiated products towards the clinic.

Trocept has generated exceptionally encouraging preclinical data. Accession Therapeutics' first drug candidate is expected to be IND stage by late 2023, followed by a pipeline of candidates engineered to make a step-change in cancer treatment.



[film] **How trocept works**  
<https://www.youtube.com/watch?v=GbvNngZXG9g>


**“Accession Therapeutics’ Trocept approach enables us to design novel highly targeted treatments with the potential to eradicate all cells in a tumour, regardless of diversity.**

**This enormous increase in the ability to target tumours and wipe out cancer cells eliminates many of the drawbacks of current immunotherapies.**

**We’re the first company to have engineered a viral point of entry to cancer cells while bypassing healthy cells - so it’s ‘gloves off’ in the fight against cancer.”**

Bent Jakobsen, PhD FMedSci, CEO

Accession Therapeutics is developing a proprietary pipeline of highly targeted immuno-oncology products with a range of therapeutic payloads.



Contact us if you'd like to discuss partnerships or collaborations.

## our team

Highly experienced in taking immuno-oncology products to the clinic.



See 'our team' page to find out more.




## creating the ideal immunotherapy

The ideal immunotherapy is highly specific to a tumour, broad in action to kill all cancer cell variants, and potent in activating the full immune system arsenal locally.

Based on a stealth cancer-targeting virus carrying a transgene for one or more antitumour or immune activator drugs, Trocept is the first approach that meets these requirements.

Watch the animation below to see how Trocept works.

Watch the animation below to see **how Trocept works**.  
<https://www.youtube.com/watch?v=GbvNdgZXG9g&t=1s>




Accession Therapeutics' proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.

As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.


Trocept's highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

The first drug candidate generated by the Trocept platform is expected to be IND stage by late 2023.




# harnessing the immune system to tackle tumour cell diversity


Trocept is a unique viral technology designed to deliver a broad and potent payload only in the cancer




Once in the cancer **Trocept** delivers a broad and multi-pronged attack.



Simultaneously it also...



Accession Therapeutics is developing a proprietary pipeline of highly targeted immuno-oncology products with a range of therapeutic payloads.



Contact us if you'd like to discuss partnerships or collaborations.

## a team with purpose

Accession Therapeutics' mission is to eradicate cancers by harnessing the immune system more powerfully than ever before. It is built around successful biotech entrepreneurs experienced in taking projects through to the clinic. This team is supported by a Board comprising experienced international healthcare investors.

### management



Ranjeet Babbra, BSc (Hons), MSc  
**Head of Quality & Strategy, Accession Executive Team**

Ranjeet has over 15 years' experience of Quality Assurance across the biotechnology and pharmaceutical industry and the NHS, with significant additional experience in project management, quality management and process improvement. A Chartered Biologist, Ranjeet has numerous QA qualifications plus a BSc (Hons) and MSc from the University of Westminster.



Dave Cole, D.Phil  
**Head of Research, Accession Executive Team**

Dave is a recognised expert in immune-oncology with over 13 years' experience, including research leading to the discovery and validation of novel drug candidates plus development of collaborations with academia and industry. In his academic career Dave worked as a principal investigator and Wellcome Trust Fellow at Cardiff University, where he also carried out postdoctoral work after he received his D.Phil in Molecular Immunology from the University of Oxford.



Andrew 'Jez' Gerry, PhD  
**COO, Accession Executive Team**

Jez is a leading immune-oncologist with expertise in preclinical safety and efficacy testing strategies for engineered cell therapies, engineered T cell receptors and novel immunotherapies for cancer, with over 14 years' experience at Adaptimmune Therapeutics. Jez obtained his PhD from The University of Reading in Cell and Molecular Biology.



Bent Jakobsen, PhD, FMedSci  
**CEO, Accession Executive Team, Founder and Board Director**

Bent is a pioneer of T cell receptor therapy for cancer with over two decades' experience of establishing and providing scientific direction to leading T cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and prior to this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge.

## management



Stephanie Bewick, PhD  
**CBO, Accession Executive Team**

Stephanie has over 20 years' experience in business development with a proven track record in negotiation of in- and out-licensing deals, setting business strategy, and raising capital in biotech companies including Mayne Pharma, Summit Therapeutics and Destiny Pharma. Stephanie has experience from the research up to Phase 3 development and has worked with multi-cultural teams in Europe, US and Asia Pacific. She has a PhD from University of Bristol and a BSc (Hons) from the University of Edinburgh.



Nick Cross  
**CFO and Executive Chairman**

Nick is a serial entrepreneur and investor with considerable Board experience in both the biotech and high tech sectors. Nick has co-founded and served as the Chairman of a number of companies including Immunocore PLC, Adaptimmune PLC, Oxford Asymmetry International PLC (now part of Evotec) and Oxford Semiconductor Ltd (now part of Toshiba).



Andy Johnson  
**Head of Chemistry, Manufacturing and Control, Accession Executive Team**

Andy has over 20 years' experience leading CMC in the biotechnology sector at Immunocore, Medigene, Avidex, Lonza and British Biotech. Andy has led CMC activities for several novel immuno-oncology products from Phase I to commercialisation



David Krige, PhD  
**Head of Translational Science, Accession Executive Team**

David has 20 years' experience leading translational science and oncology programmes across biotech companies and charities including PsiOxus, Immunocore and Cancer Research UK, with specific experience in clinical viral products. He has a PhD in Biochemistry from the University of London.



Hardev Pandha, MB ChB, FRCP, FRACP, PhD, FRSB  
**Medical Director, Accession Executive Team**

Hardev is a clinician scientist and medical oncologist with over 20 years' experience leading clinical studies in oncology, including several viral products. He trained in medicine in Birmingham and London.



Alan Parker, PhD  
**CSO and Founder of Trocept**

Alan is an expert in viral gene delivery, particularly in the oncology setting, having worked in the field for almost two decades following a PhD at the University of Birmingham. He is Professor of Translational Virotherapies at the School of Medicine, Cardiff University, where his work is funded by Cancer Research UK, Cancer Research Wales and Tenovus Cancer Care amongst others.



## board



Nick Cross  
**CFO and Executive Chairman**

Nick is a serial entrepreneur and investor with considerable Board experience in both the biotech and high tech sectors. Nick has co-founded and served as the Chairman of a number of companies including Immunocore PLC, Adaptimmune PLC, Oxford Asymmetry International PLC (now part of Evotec) and Oxford Semiconductor Ltd (now part of Toshiba).



Bent Jakobsen, PhD, FMedSci  
**CEO, Accession Executive Team, Founder and Board Director**

Bent is a pioneer of T cell receptor therapy for cancer with over two decades' experience of establishing and providing scientific direction to leading T cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and prior to this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge.



Hans Ivar Robinson  
**Board Director**

Hans Ivar is a Director of Accession Therapeutics and CEO/ Chairman of Birk Venture, a Norwegian investment company focused on the life sciences sector. He brings broad industrial and investment experience from the pharmaceutical and biotechnology industry.



Johnny Zou  
**Board Director**

Johnny is a Director of Accession Therapeutics and Co-Head of Primavera Venture Partners, the VC arm of Primavera Capital Group, focusing on early-stage innovative tech companies in artificial intelligence, the industrial internet, and healthcare. He has led investments in some of the world's and China's most innovative companies in areas such as AI drug discovery, genomics and next generation immunotherapies.



Sin Chong, PhD  
**Board Observer**

Yoke Sin Chong is Managing Partner at iGlobe Partners.

## scientific advisors



Associate Prof Dr Amanda Tatler  
**Principal Research Fellow, Nottingham University**

Amanda is a recognised expert in the mechanisms driving tissue remodelling in chronic lung diseases (including idiopathic pulmonary fibrosis, asthma, COPD) and viral infections (such as influenza, SARS-CoV-2). In particular, Amanda's research focusses on understanding the role of integrins in lung fibrosis, which has attracted major interest from pharmaceutical companies developing new drugs to treat this condition.



Prof Chris O'Callaghan  
**Oxford University**

Chris is a recognised expert in human immunology and has made major contributions to understanding immune system function in many human diseases, including cancer, infection, atherosclerosis and autoimmune disease. Chris' research focusses on the function of the molecules and pathways involved in the immune response and the role of the immune system and inflammation in disease with a view to accelerate the design of better treatments for human diseases.



Prof John Marshall  
**Centre Lead, Queen Mary's University London**

John is an internationally recognised expert in integrin biology and has played a key role in developing multiple integrin targeting agents for therapy and diagnostics. His research focuses on the biology of tumour invasion with a particular interest in the roles of the adhesion molecules expressed on the cell surface that mediate this process with a focus on integrins that are the principal family of adhesion molecules that mediate interaction between cells and the extracellular matrix (ECM).

## careers

Accession Therapeutics is now recruiting a world-class team to establish its R&D facility in Oxfordshire, UK.

Please go to our career page or LinkedIn page for more details.

If you are interested in joining a highly creative, dynamic and fast-developing organisation with an open, friendly non-hierarchical culture, please send your cover letters and CVs to:

[joinus at accessiontherapeutics.com](mailto:joinus@accessiontherapeutics.com).

Salaries are competitive; Other benefits include pension scheme, life insurance and private health insurance.

We look forward to meeting you and discussing your future career.

## Bent Jakobsen starts novel immune-oncology firm Accession Therapeutics **Primavera Venture Partners and Birk Venture among first investors.**

**Oxford, UK, September 20 2021** – Accession Therapeutics, which is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has closed the first tranche of a long-term funding round. With financing from Primavera Venture Partners and Birk Venture alongside an international syndicate of experienced biotech investors, the funding will enable the company to progress its lead programme into clinical trials and build a pipeline of new cancer therapies using its Trocept technology platform. The CEO of Accession Therapeutics is Bent Jakobsen, PhD FMedSci, the scientific founder of Adaptimmune and Immunocore and pioneer of T cell receptor therapy for cancer. He is joined on the company's Board by Johnny Zou of Primavera Venture Partners and Hans Ivar Robinson of Birk Venture.

The team joining Accession Therapeutics is highly experienced in taking products to the IND or early clinical trial stage rapidly and effectively. Hires will be announced shortly. Proceeds of the fundraising will also be used to establish the company's new headquarters in Oxford. The company's strategy is to partner its products at the IND or early clinical trial stage point.

Accession Therapeutics believes that the ideal immunotherapy should have three characteristics – highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal. By engineering viruses exclusively directed to cancer cells and carrying a transgene coding for one or more antitumour or immune activator drugs, Trocept products meet these three requirements. The antitumour or immune activator drugs, and immune system activation caused by cancer cell lysis after viral infection, combine synergistically to give a broad and potent response with limited toxicity.

The company's lead product has shown encouraging data in in vivo models. Accession Therapeutics' elegant approach, based on over a decade's research, is believed to be the first time that a virus has been genetically modified to exclusively target cancer cells (cancer tropism). This engineered specificity targets some of the hardest to treat and most widespread forms of the disease, such as breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Bent Jakobsen, PhD FMedSci, CEO of Accession Therapeutics, said, 'The past decade has demonstrated the promise of harnessing the immune system against cancers but, in the majority of cancers and patients, current treatment concepts fail to deal with the huge diversity of cancer cells leading to transient responses followed by progressive disease. Accession Therapeutics' Trocept approach enables us to design novel treatments with the potential to deal radically with the full variety and escape mechanisms of tumour cells. We would like to thank Primavera Venture Partners, Birk Venture and our other investors for their endorsement and we look forward to working with them as we progress our lead programme towards the clinic and advance the portfolio.'

Johnny Zou, co-head of Primavera Venture Partners, said, 'Primavera Venture Partners is excited to be involved in a new venture with such promising technology managed by a team with an outstanding record in the immune-oncology field. Accession Therapeutics provides a unique opportunity for making a huge step change, and within a relatively limited time-frame, in the treatment of many cancers.'

Hans Ivar Robinson, CEO and Chairman of Birk Venture, said, 'We are very excited by the potential of Accession Therapeutics' elegant Trocept technology in hard-to-treat cancers. Birk Venture looks forward to using its expertise gained from extensive oncology investment to support the company's development of much needed novel cancer therapeutics.'

--ENDS--

PTO

For more information, please contact  
Emma Palmer Foster, Communications  
**comms@accessiontherapeutics.com**  
Tel +44 (0) 7880 787185

### **About Accession Therapeutics**

Accession Therapeutics is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. Led by T cell receptor therapy pioneer Be

nt Jakobsen, PhD FMedSci, the company is leveraging its Trocept platform technology to develop a portfolio of next generation products to the IND/early clinical trial stage. By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal.

The effect of the antitumour drug and immune system activation caused by cancer cell lysis after viral infection combine synergistically to give this broad and potent response. Dr Jakobsen is a founder of Adaptimmune and Immunocore which are both now listed on NASDAQ. Accession Therapeutics recently closed the first tranche of a long-term funding round, supported by Primavera Venture Partners, Birk Venture and other international biotech investors. It is establishing headquarters in Oxford, UK.

### **About Primavera Venture Partners**

Primavera Venture Partners (PVP) is the venture capital arm of Primavera Capital Group, a premier China-based global investment firm with portfolio companies including Alibaba, Ant Group, ByteDance, Junlebao, Kuaishou, Laobaixing, Xpeng, Yum China, among others. PVP focuses on early-stage innovative tech companies in artificial intelligence, industrial Internet, and healthcare etc.

### **About Birk Venture**

Birk Venture is a privately held Norwegian based Investment Company exclusively focusing on the life science sector. The company was founded by Hans Ivar Robinson in 2010. Our vision is to transform unique innovations and technologies into excellent businesses in the health care sector. We offer capital to young companies with significant growth prospects, and we take an active role in the development of our early stage investments. Our approach is always to take a long term view in our strategic investment decisions which are based on broad industrial experience from the pharmaceutical and biotechnology industry.

## Cancer leader Professor Alan Parker joins Accession Therapeutics Co-inventor of Trocept platform to guide immuno-oncology pipeline growth

**Oxford, UK, January 26 2022** – Accession Therapeutics, which is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, is pleased to announce that Alan Parker, Professor of Translational Virotherapies at Cardiff University, has joined the company. Professor Parker is co-inventor of its proprietary Trocept platform, and has been appointed Chief Scientific Officer of its Trocept Therapeutics subsidiary in which the technology is being developed. Based on over a decade of work, the first Trocept product is expected to enter the clinic within the next three years.

Based at the School of Medicine, Cardiff University since 2013, Professor Parker will continue to lead his group there alongside his role at Accession Therapeutics, with the two teams maintaining a close collaborative relationship. At the University he is Head of Solid Cancers and leads the targeted therapeutic programme of the Wales Cancer Research Centre (funded by Health and Care Research Wales). His laboratory is also supported by Cancer Research UK, Cancer Research Wales and Tenovus Cancer Care. Professor Parker received his PhD at the CRUK Institute for Cancer Studies at the University of Birmingham in 2003.

Accession Therapeutics recently closed the first tranche of a long-term funding round with Primavera Venture Partners, Birk Venture and an international syndicate of biotech investors. By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, the company's Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal.

Alan Parker, PhD, CSO of Trocept Therapeutics, said, 'As an immuno-oncology drug generation platform Trocept has the potential to transform the treatment of recalcitrant cancers. I'm delighted to join the expert team to help generate a pipeline of novel and effective cancer therapeutics with minimal side effects.'

Bent Jakobsen, PhD FMedSci, CEO of Accession Therapeutics, said, 'As we work to eradicate cancers by harnessing the immune system more powerfully than ever before, Alan's extensive knowledge of viral gene delivery in the oncology setting will be invaluable. He is an excellent complement to our existing skills base and we are delighted to welcome him to the company.'



--ENDS--

For more information, please contact  
Emma Palmer Foster, Communications  
[comms@accessiontherapeutics.com](mailto:comms@accessiontherapeutics.com)  
Tel +44 (0) 7880 787185

### **About Accession Therapeutics**

Accession Therapeutics is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. Led by T cell receptor therapy pioneer Bent Jakobsen, PhD FMedSci, the company is leveraging its Trocept platform technology to develop a portfolio of next generation products to the IND/early clinical trial stage. By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal. The effect of the antitumour drug and immune system activation caused by cancer cell lysis after viral infection combine synergistically to give this broad and potent response, as illustrated in the animation here: <https://bit.ly/3r8WgPu>

Dr Jakobsen is a founder of Adaptimmune and Immunocore which are both now listed on NASDAQ. Accession Therapeutics recently closed the first tranche of a long-term funding round, supported by Primavera Venture Partners, Birk Venture and other international biotech investors. It is establishing its laboratory and office facilities at the Oxford Business Park, UK. [www.accessiontherapeutics.com](http://www.accessiontherapeutics.com)

## Accession Therapeutics raises £16.6m to advance potent immunotherapies towards clinical trials

### **New Singaporean investor iGlobe Partners backs rapidly developing preclinical pipeline at immunotherapy pioneer's company**

**Oxford, UK, November 21 2022** – Accession Therapeutics, which is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has raised £16.6m to advance its two lead preclinical programmes to clinical trials. New investors, including the Singaporean fund iGlobe Partners, join Primavera Venture Partners, Birk Venture and biotech angels in backing the potential of the company's Trocept platform to deliver highly potent anticancer payloads with minimal toxicity. The CEO and founder of Accession Therapeutics is Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer.

The funding will also enable the company to progress its earlier stage pipeline and follows last year's seed round of £11m. As part of the financing round, Managing Partner of iGlobe Partners Dr Yoke Sin Chong takes a Board observer role.

The Trocept approach uses an adenovirus which has been genetically modified by Professor Alan Parker's laboratory at Cardiff University to exclusively target cancer cells. Accession Therapeutics believes that this makes it the first company to be able to develop therapeutics with a discriminatory viral point of entry into cancer cells. With the virus carrying a transgene coding for one or more agents (such as antitumour or immune activator drugs or prodrugs), this engineered specificity enables the company to target some of the hardest to treat and most widespread forms of the disease, such as breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Accession Therapeutics' two lead programmes are each delivering a different therapeutic payload targeted to cancer cells via integrin binding. They are expected to reach the IND stage at the end of 2023 and enter the clinic at the beginning of 2024.

Bent Jakobsen, PhD FMedSci, CEO of Accession Therapeutics, said, 'We are delighted to have closed so soon this second fundraising round with the support of new investors, including iGlobe Partners, and our existing investors. With the Trocept platform Accession Therapeutics believes it has the ability to create ideal immunotherapies, specific in target and potent in effect with minimal toxicity. We're focused on advancing our lead programmes to the clinic as rapidly as possible.'

Managing Partner of iGlobe Partners Dr Yoke Sin Chong, said, 'iGlobe Partners is delighted to support Accession Therapeutics in its strategy to bring about a step change in the effectiveness of cancer immunotherapies. We look forward to working with the company as it develops an exciting pipeline of drug candidates to induce, attract, activate and target broad and potent immune responses against cancer.'

--ENDS--

For more information, please contact  
Emma Palmer Foster, Communications  
**comms@accessiontherapeutics.com**  
Tel +44 (0) 7880 787185



**About Accession Therapeutics**

Accession Therapeutics is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. Led by T cell receptor therapy pioneer Bent Jakobsen, PhD FMedSci, the company is leveraging its Trocept platform technology to develop a portfolio of next generation products to the IND/early clinical trial stage. By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal. The effects of the antitumour drug and immune system activation caused by cancer cell lysis after viral infection combine synergistically to give this broad and potent response, as illustrated in the animation here: <https://bit.ly/3r8WgPu>

Dr Jakobsen is a founder of Adaptimmune and Immunocore which are both now listed on NASDAQ. Accession Therapeutics is backed by iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors. It is based at ARC Oxford in the UK. [www.accessiontherapeutics.com](http://www.accessiontherapeutics.com)

**About iGlobe Partners**

Founded in 1999, iGlobe Partners is a premier venture capital fund manager investing in early-stage technology startups in the area of Smart Cities, Fintech, Healthtech and Biotech. First established in Silicon Valley and headquartered in Singapore today, the firm has an extensive global network and a strong track record of enabling startups to scale game-changing innovations across geographies. The team has managed funds exceeding US\$400 million and has continually delivered top-quartile fund performance to investors, giving rise to multiple unicorns and successful exits including Unity Software (NYSE: U), Twist Bioscience (NASDAQ: TWST), ACSL (TYO: 6232), Matterport (NASDAQ: MTTR), Hippo Holdings (NYSE: HIPO), Ginkgo Bioworks (NYSE: DNA) and NerdWallet (NASDAQ: NRDS).

**About Primavera Venture Partners**

Primavera Venture Partners (PVP) is the venture capital arm of Primavera Capital Group, a premier China-based global investment firm with portfolio companies including Alibaba, Ant Group, ByteDance, Junlebao, Kuaishou, Laobaixing, Xpeng, Yum China, among others. PVP focuses on early-stage innovative tech companies in artificial intelligence, industrial Internet, and healthcare etc.

**About Birk Venture**

Birk Venture is a privately held Norwegian based Investment Company exclusively focusing on the life science sector. The company was founded by Hans Ivar Robinson in 2010. Our vision is to transform unique innovations and technologies into excellent businesses in the health care sector. We offer capital to young companies with significant growth prospects, and we take an active role in the development of our early stage investments. Our approach is always to take a long term view in our strategic investment decisions which are based on broad industrial experience from the pharmaceutical and biotechnology industry.

221117\_AT Press release\_FINANCING.pdf  
Download PDF



Accession Therapeutics is attending the J.P. Morgan 41st Annual Healthcare Conference – January 2023

**We are interested in discussing partnerships, collaborations and investment so please get in touch if you would like to meet us at the event in San Francisco, January 9-12 2023.**



Biocentury Emerging Company Profile –  
Accession: precisely targeted oncolytic viruses

**Bent Jakobsen's newest biotech is replacing the virus' natural tropisms with an integrin-based cancer targeting mechanism – read the article by Richard Guy, Biopharma Analyst, [here](#) >**



[bc-accession-precisely-targeted-oncolytic-viruses.pdf](#)  
Download PDF

## Accession Therapeutics presented some of the exciting preclinical data for our lead programme

**Accession Therapeutics presented some of the exciting preclinical data for our lead programme #TROCEPT-01 at the recent 37th Annual Meeting of the @Society for Immunotherapy of Cancer.**

Working with our partners at @Cardiff University we demonstrated the potential of #TROCEPT products to generate high concentrations of potent anti-tumour drugs selectively in cancer cells with minimum systemic toxicity.

In in vitro and in vivo studies #TROCEPT-01 was shown to traffic to tumour cells highly selectively where its immune checkpoint inhibitor transgene was functionally expressed. Minimal levels of #TROCEPT-01 were detected outside of the tumour.

Read more about how #TROCEPT, a novel cancer-selective delivery technology, is powering our pipeline here.



112122\_ECP\_Accession.pdf  
[Download PDF](#)

## Chief Business Officer appointed at Accession Therapeutics as company prepares for clinical trials



### **Chief Business Officer appointed at Accession Therapeutics as immune-oncology company prepares for clinical trials in 2024**

#### **Dr Stephanie Bewick joins with extensive partnering and business development experience**

**Oxford, UK, July 19 2023** – Accession Therapeutics, which is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has recently expanded its management team with the appointment of experienced executive Dr Stephanie Bewick to the new role of Chief Business Officer. Dr Bewick, who has been involved in multiple licensing deals and fund-raising transactions, joins the company as its lead programme Trocept-01 (ATTR-01) progresses through IND-enabling studies. In another new role, Dr Jez Gerry has been promoted to Chief Operating Officer from his position as Head of Preclinical Development.

Dr Bewick has worked across a range of international pharmaceutical and biotechnology companies, including Summit Therapeutics and Mayne Pharma covering a variety of therapeutic areas and in- and out-licensing deals. She joins from Destiny Pharma plc where she recently led the exclusive US collaboration and co-development deal for its Phase 3-ready anti-infective asset with Sebela Pharmaceuticals and played a pivotal role in fund-raising.

Accession Therapeutics' Trocept approach uses detargeted and retargeted adenovirus making immunotherapy more specific to cancer cells and in turn more potent than existing technologies, with minimal toxicity. Its lead programme's drug payload is targeted to cancer cells via integrin binding and is expected to enter the clinic in the first half of 2024 for solid tumours such as those of the head and neck, pancreatic, ovarian and breast.

Dr Stephanie Bewick, CBO of Accession Therapeutics, said, 'Founded by a pioneer in immune-oncology, Accession Therapeutics has a novel approach with the potential to make a step-change in the treatment of cancer, and I'm delighted to join the company at this exciting stage of its development. With our strategy to partner at the IND or early clinical stage, together with our developing pipeline and the flexibility of the platform, we're looking forward to developing valuable collaborations and partnerships in the coming months.'

Bent Jakobsen, PhD FMedSci, CEO of Accession Therapeutics, said, 'As we develop into a clinical stage company, I'm pleased to welcome Stephanie to the management team, where her partnering and financing experience will be very valuable to us. Jez's promotion is also a marker of Accession Therapeutics' maturation, and I look forward to working with both of them in their new roles.'

--ENDS--  
PTO

For more information, please contact  
Emma Palmer Foster, Communications  
comms@accessiontherapeutics.com  
Tel +44 (0) 7880 787185

### **About Accession Therapeutics**

Accession Therapeutics is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. Led by T cell receptor therapy pioneer Bent Jakobsen, PhD FMedSci, the company is leveraging its Trocept platform technology to develop a portfolio of next generation products to the IND/early clinical trial stage.

By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal. The effects of the antitumour drug and immune system activation caused by cancer cell lysis after viral infection combine synergistically to give this broad and potent response as illustrated in this animation here. Accession Therapeutics believes that this makes it the first company to be able to develop therapeutics with a discriminatory viral point of entry into cancer cells. With the virus carrying a transgene coding for one or more agents (such as antitumour or immune activator drugs or prodrugs), this engineered specificity enables the company to target some of the hardest to treat and most widespread forms of the disease, such as breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Dr Jakobsen is a founder of Adaptimmune and Immunocore which are both now listed on NASDAQ. Accession Therapeutics is backed by iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors. It is based at ARC Oxford in the UK.

230719\_New CBO Accession Therapeutics 18 07 23 FINAL.pdf  
[Download PDF](#)

## Key references for the Trocept platform

Please contact us for any further information

### Most relevant papers

1/ Uusi-Kerttula, H., et al., Ad5(NULL)-A20: A Tropism-Modified,  $\alpha\beta_6$  Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. **Clin Cancer Res**, 2018. **24(17)**: p. 4215-4224.

<https://aacrjournals.org/clincancerres/article/24/17/4215/281635/Ad5NULL-A20-A-Tropism-Modified-v-6-Integrin>

2/ Davies, J.A., et al., Efficient Intravenous Tumor Targeting Using the  $\alpha\beta_6$  Integrin-Selective Precision Virotherapy Ad5(NULL)-A20. **Viruses**, 2021. **13(5)**.

<https://www.mdpi.com/1999-4915/13/5/864>

3/ Cole D, Khanolkar R, Davies J, et al

1349 TROCEPT mediated in-tumor delivery of immune checkpoint inhibitors reduces systemic toxicity risks and boosts immune activation. **Journal for ImmunoTherapy of Cancer** 2022;10

[https://jitc.bmj.com/content/10/Suppl\\_2/A1400](https://jitc.bmj.com/content/10/Suppl_2/A1400)

### Related papers

4/ Waddington, S.N., et al., Adenovirus serotype 5 hexon mediates liver gene transfer. **Cell**, 2008. **132(3)**: p. 397-409.

<https://www.sciencedirect.com/science/article/pii/S0092867408001165>

5/ Parker, A.L., et al., Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. **Blood**, 2006. **108(8)**: p. 2554-61.

<https://ashpublications.org/blood/article/108/8/2554/22541/Multiple-vitamin-K-dependent-coagulation-zymogens>

6/ Alba, R., et al., Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. **Blood**, 2009. **114(5)**: p. 965-71.

<https://ashpublications.org/blood/article/114/5/965/103726/Identification-of-coagulation-factor-F-X-binding>

7/ Alba, R., et al., Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. **Blood**, 2010. **116(15)**: p. 2656-64.

<https://ashpublications.org/blood/article/116/15/2656/27697/Biodistribution-and-retargeting-of-FX-binding>

8/ Parker, AL, et al, Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. **J Virol**, 2009. **83(1)**: p. 479-83.

<https://journals.asm.org/doi/10.1128/JVI.01878-08>

9/ Parker, A.L., et al., Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. **J Virol**, 2007. **81(7)**: p. 3627-31.

<https://journals.asm.org/doi/10.1128/JVI.02786-06>

10/ Waddington, S.N., et al., Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. **J Virol**, 2007. **81(17)**: p. 9568-71.

<https://journals.asm.org/doi/10.1128/JVI.00663-07>

11/ Uusi-Kerttula, H., et al., Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies. **Hum Gene Ther**, 2015. **26(5)**: p. 320-9.

[https://www.liebertpub.com/doi/10.1089/hum.2015.015?url\\_ver=Z39.88-2003&rfr\\_id=ori%3Arid%3Acrossref.org&rfr\\_dat=cr\\_pub++0pubmed](https://www.liebertpub.com/doi/10.1089/hum.2015.015?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)

12/ Uusi-Kerttula, H., et al., Pseudotyped  $\alpha\beta_6$  integrin-targeted adenovirus vectors for ovarian cancer therapies. **Oncotarget**, 2016. **7(19)**: p. 27926-37.

<https://www.oncotarget.com/article/8545/text/>

## Key references for the Trocept platform

Please contact us for any further information

### Relevant reviews and commentaries

Cunliffe, T.G., E.A. Bates, and A.L. Parker, Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. **Cancers (Basel)**, 2020. **12(11)**.  
<https://www.mdpi.com/2072-6694/12/11/3327>

Teijeira Crespo, A., et al., Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. **Immunology**, 2021. **163(4)**: p. 389-398.  
<https://onlinelibrary.wiley.com/doi/10.1111/imm.13323>

Uusi-Kerttula, H., et al., Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. **Viruses**, 2015. **7(11)**: p. 6009-42.  
<https://www.mdpi.com/1999-4915/7/11/2923>

Uusi-Kerttula, H. and A.L. Parker, Precision virotherapies: Coming soon. **Oncotarget**, 2018. **9(86)**: p. 35605-35606.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235024/>

Coughlan, L., et al., Tropism-modification strategies for targeted gene delivery using adenoviral vectors. **Viruses**, 2010. **2(10)**: p. 2290-355.  
<https://www.mdpi.com/1999-4915/2/10/2290>

Accession Therapeutics Limited,  
Building 7600, The Quorum,  
Alec Issigonis Way,  
ARC Oxford North, OX4 2JZ

Website: [www.accessiontherapeutics.com](http://www.accessiontherapeutics.com)  
Email: [info@accessiontherapeutics.com](mailto:info@accessiontherapeutics.com)  
Careers: [joinus@accessiontherapeutics.com](mailto:joinus@accessiontherapeutics.com)  
[www.linkedin.com/company/accession-therapeutics-limited](http://www.linkedin.com/company/accession-therapeutics-limited)

